2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B1794A
    Thiethylperazine dimaleate 1179-69-7 99.99%
    Thiethylperazine dimaleate, a phenothiazine derivate, is an orally active and potent dopamine D2-receptor and histamine H1-receptor antagonist. Thiethylperazine dimaleate is also a selective ABCC1activator that reduces amyloid-β (Aβ) load in mice. Thiethylperazine dimaleate has anti-emetic, antipsychotic and antimicrobial effects.
    Thiethylperazine dimaleate
  • HY-N0092S
    Inosine-2,8-d2 697807-01-5 99.69%
    Inosine-2,8-d2 is the deuterium labeled Inosine. Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A1 (A1R) and A2A (A2AR) receptors.
    Inosine-2,8-d2
  • HY-N0210S
    D-Galactose-13C 70849-30-8 ≥98.0%
    D-Galactose-13C is the 13C labeled D-Galactose. D-Galactose is a natural aldohexose and C-4 epimer of glucose.
    D-Galactose-13C
  • HY-N0304S
    L-DOPA-d6 713140-75-1 ≥99.0%
    L-DOPA-d6 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease.
    L-DOPA-d6
  • HY-N10756
    Hyp9 3118-34-1 99.90%
    Hyp9 is a transient receptor potential canonical 6 (TRPC6)-specific agonist. Hyp9 can be used for the research of spinal cord injury (SCI).
    Hyp9
  • HY-P0069A
    L-JNKI-1 99.01%
    L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK.
    L-JNKI-1
  • HY-P1025A
    M40 TFA
    M40 TFA is the TFA salt form of M40. M40 TFA is an antagonist or a weak agonist for galanin receptor depending on different subtypes of galanin receptors in the brain, hypothalamus, hippocampus, amygdala and pancreas.
    M40 TFA
  • HY-P10440
    Cdk5i peptide 2298317-00-5 99.83%
    Cdk5i peptide is a CDK5 inhibitory peptide with high binding affinity for Cdk5/p25 (Kd of 0.17 μM), which can block the interaction between CDK5 and p25 and reduce the kinase activity of CDK5/p25. Cdk5i peptide can be used in the stud y of neurodegenerative diseases.
    Cdk5i peptide
  • HY-P1132A
    Galanin (1-29)(rat, mouse) TFA 99.83%
    Galanin (1-29)(rat, mouse) TFA is a non-selective galanin receptor agonist, with Kis of 0.98, 1.48 and 1.47 nM for GAL1, GAL2 and GAL3, respectively. Anticonvulsant effect.
    Galanin (1-29)(rat, mouse) TFA
  • HY-P1294A
    α-Helical CRF(9-41) TFA 99.90%
    α-Helical CRF(9-41) TFA is a competitive CRF2 receptor antagonist with KB of ~100 nM. α-Helical CRF(9-41) TFA is also a partial agonist of CRF1 receptor with an EC50 of 140 nM.
    α-Helical CRF(9-41) TFA
  • HY-P1479A
    Calmodulin-Dependent Protein Kinase II(290-309) acetate 98.45%
    Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC50 of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II.
    Calmodulin-Dependent Protein Kinase II(290-309) acetate
  • HY-P3445A
    Anrikefon acetate 2584931-05-3 99.25%
    Anrikefon (HSK21542) acetate is a kappa opioid receptor agonist with analgesic effect.
    Anrikefon acetate
  • HY-P5807A
    Cn2 toxin TFA 98.13%
    Cn2 toxin TFA (β-Mammal toxin Cn2 TFA) is a single-chain β-scorpion neurotoxic peptide that is the main toxin in scorpion venom. Cn2 toxin (TFA) specifically targets mammalian voltage-gated sodium channels (VGSC) Nav1.6.
    Cn2 toxin TFA
  • HY-P99403
    Refanezumab 1233953-61-1 ≥99.0%
    Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke.
    Refanezumab
  • HY-U00106
    Cimetropium Bromide 51598-60-8
    Cimetropium Bromide (DA-3177) is a mAChR antagonist for long-term treatment of irritable bowel syndrome.
    Cimetropium Bromide
  • HY-U00429
    NOT Receptor Modulator 1 1015231-98-7 98.61%
    NOT Receptor Modulator 1 is a nuclear receptor Nurr-1/NOT modulator extracted from patent WO 2008034974 A1, Example 39 in table1.
    NOT Receptor Modulator 1
  • HY-100646A
    (Z)-10-Hydroxynortriptyline 47132-19-4 ≥99.0%
    (Z)-10-Hydroxynortriptyline is a metabolite of Nortriptyline. Nortriptyline is a tricyclic antidepressant and the main active metabolite of Amitriptyline, and is used to relieve the symptoms of depression.
    (Z)-10-Hydroxynortriptyline
  • HY-101039A
    AR-M 1000390 hydrochloride 209808-47-9 98.20%
    AR-M 1000390 hydrochloride is an exceptionally selective, potent δ opioid receptor agonist with an EC50 of 7.2±0.9 nM for δ agonist potency.
    AR-M 1000390 hydrochloride
  • HY-101355A
    CGP 20712 dihydrochloride 1216905-73-5 ≥99.0%
    CGP 20712 dihydrochloride is a highly selective β1-adrenoceptor antagonist with an IC50 of 0.7 nM. CGP 20712 dihydrochloride exhibits ~10,000-fold selectivity over β2-adrenoceptors.
    CGP 20712 dihydrochloride
  • HY-101357A
    CP 93129 dihydrochloride 879089-64-2 ≥99.0%
    CP 93129 dihydrochloride is a potent 5HT1B receptor agonist. CP 93129 dihydrochloride has the potential for parkinson's disease research.
    CP 93129 dihydrochloride
Cat. No. Product Name / Synonyms Application Reactivity